Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
500 mcg 60 capsules $159 Growth hormone releasing hormone (GHRH) analog that increases IGF-1 levels in both men and women, which affects metabolism and can help decrease visceral adipose tissue
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Patients from Miami, Miami Beach, Aventura, Sunny Isles Beach, Hollywood, Hallandale Beach, Fort Lauderdale, Boca Raton, Delray Beach, Boynton Beach, West Palm Beach, Jupiter, Plantation, Coral Springs, Davie, Weston, Deerfield Beach, and surrounding communities can discuss peptide therapy options without traveling to the office
Peptide Vials (HGH 191AA, 10 IU each) Each 10 IU (3.33 mg) vial covers part of a week as doses rise across the titration
A properly stored lyophilized semaglutide vial contains a single white-to-off-white cake or powder at the bottom
Within peptide and recovery-focused research models, this combination is referenced in studies involving tissue-repair mechanisms, angiogenesis modelling, and cellular-response investigation
